Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Isoray Inc (ISR)

Isoray Inc (ISR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,923
  • Shares Outstanding, K 142,113
  • Annual Sales, $ 10,800 K
  • Annual Income, $ -7,270 K
  • 60-Month Beta 1.38
  • Price/Sales 3.82
  • Price/Cash Flow N/A
  • Price/Book 0.71
Trade ISR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.06
  • Most Recent Earnings -0.03 on 11/10/22
  • Next Earnings Date 02/14/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.01
  • Number of Estimates 1
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year -0.01
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2393 +25.32%
on 12/28/22
0.3000 -0.03%
on 01/27/23
+0.0419 (+16.24%)
since 12/27/22
3-Month
0.2393 +25.32%
on 12/28/22
0.4100 -26.85%
on 11/21/22
-0.0258 (-7.92%)
since 10/27/22
52-Week
0.1922 +56.04%
on 09/29/22
0.4499 -33.34%
on 08/18/22
-0.0531 (-15.04%)
since 01/27/22

Most Recent Stories

More News
ISORAY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Isoray, Inc - ISR

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Isoray, Inc (“the Company”) (NYSE: ISR)...

ISR : 0.2977 (+0.92%)
Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of 29.41% and 15.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PROF : 12.65 (-2.69%)
ISR : 0.2977 (+0.92%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALO, ISR, FCRD, SESN

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TALO : 20.43 (-2.44%)
ISR : 0.2977 (+0.92%)
FCRD : 4.63 (+1.98%)
SESN : 0.6340 (+3.32%)
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT

Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based...

ISR : 0.2977 (+0.92%)
ISR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Isoray, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Isoray, Inc. (NYSE: ISR) and Viewpoint Molecular Targeting, Inc. is fair to Isoray shareholders.

ISR : 0.2977 (+0.92%)
IsoRay (ISR) Reports Q4 Loss, Misses Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0% and 13.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ISR : 0.2977 (+0.92%)
TARO : 30.72 (+0.39%)
Inflation Report Due in Canada Next Week

Monday U.S. Economic Lookahead NAHB home builders' index (Sept.) Featured Earnings Autozone ...

AZO : 2,366.67 (-2.01%)
NEOG : 20.05 (+0.86%)
APOG : 44.99 (+0.72%)
SFIX : 4.93 (+11.54%)
ISR : 0.2977 (+0.92%)
GIS : 77.90 (+1.43%)
LEN : 100.60 (+0.58%)
TCOM : 39.42 (-1.60%)
COST : 503.50 (+1.04%)
ACN : 277.27 (+1.10%)
FDX : 190.50 (+0.19%)
INM : 1.8200 (-4.71%)
Champions Oncology, Inc. (CSBR) Reports Q1 Loss, Tops Revenue Estimates

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -300% and 2.27%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

CSBR : 4.12 (+1.73%)
ISR : 0.2977 (+0.92%)
Catalent (CTLT) Q4 Earnings Surpass Estimates

Catalent (CTLT) delivered earnings and revenue surprises of 3.48% and 0.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CTLT : 53.65 (+2.64%)
ISR : 0.2977 (+0.92%)
Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference

RICHLAND, Wash., June 21, 2022 (GLOBE NEWSWIRE) -- The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating...

ISR : 0.2977 (+0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the...

See More

Key Turning Points

3rd Resistance Point 0.3165
2nd Resistance Point 0.3083
1st Resistance Point 0.3016
Last Price 0.2977
1st Support Level 0.2867
2nd Support Level 0.2785
3rd Support Level 0.2718

See More

52-Week High 0.4499
Fibonacci 61.8% 0.3515
Fibonacci 50% 0.3210
Last Price 0.2977
Fibonacci 38.2% 0.2906
52-Week Low 0.1922

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar